Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the ...

Pfizer’s vaccine – called Abrysvo – is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, the same label that the FDA gave to ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

Wilson OKs plan for 1-million-square-foot warehouse The plan, known as Easton Commerce Park, would occupy the former 106.2-acre Pfizer Pigments site on Wood Avenue.